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Abstract
The vitamin D receptor (VDR), primarily known as a crucial mediator of calcium homeostasis and metabolism, has been 
shown to play a significant role in various cancer entities. Previous studies have focused on vitamin D and its receptor in 
gynecological cancers, noting that the receptor is upregulated in epithelial ovarian cancer (EOC). The aim of this study is 
to analyze the prognostic impact of VDR and its functional significance in ovarian cancer. Through immunohistochemistry, 
VDR staining was examined in 156 ovarian cancer samples. Evaluation of VDR staining was conducted in the nucleus and 
the cytoplasm using the semi-quantitative immunoreactive score, and the scores were classified into high- and low-level 
expressions. Expression levels were correlated with clinical and pathological parameters as well as with overall survival 
to assess for prognostic impact. Differences in cytoplasmic VDR expression were identified between the histological sub-
types (p = 0.001). Serous, clear cell, and endometrioid subtypes showed the highest staining, while the mucinous subtype 
showed the lowest. Cytoplasmic VDR correlated with higher FIGO stage (p = 0.013; Cc = 0.203), positive lymph node status 
(p = 0.023; Cc = 0.236), high-grade serous histology (p = 0.000; Cc = 0.298) and grading from the distinct histological sub-
types (p = 0.006; Cc = − 0.225). Nuclear VDR did not correlate with clinicopathological data. High cytoplasmic expression 
of VDR was associated with impaired overall survival (HR 2.218, 32.5 months vs. median not reached; p < 0.001) and was 
confirmed as a statistically independent prognostic factor in the Cox regression multivariate analysis. Additional knowledge 
of VDR as a biomarker and its interactions within the mitogen-activated protein kinase (MAPK) signaling pathway could 
potentially improve the prognosis of therapeutic approaches for specific subgroups in EOC.
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Abbreviations
Cc  Correlation coefficient
CI  Confidence interval
EMT  Epithelial–mesenchymal transition
EOC  Epithelial ovarian cancer
ERK  Extracellular-signal-regulated kinase
FFPE  Formalin fixed and paraffin embedded
FIGO  Fédération Internationale de Gynécologie et 
d’Obstétrique
IRS  Immunoreactive score
MAPK  Mitogen-activated protein kinase
OS  Overall survival
SD  Standard deviation
VDR  Vitamin D receptor VDR
VDRE  Vitamin D response element
WHO  Word Health Organization
Introduction
Ovarian cancer is one of the most lethal tumor entities 
(Siegel et al. 2019). Insufficient screening methods and ris-
ing resistances to chemotherapy over the clinical course 
further contribute to the relatively low 5-year survival rate 
of around 45% (Baldwin et al. 2012; Siegel et al. 2019). 
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Recommended therapy consists of cytoreductive surgery 
followed by adjuvant platinum-based chemotherapy com-
bined with anti-angiogenic agents or followed by poly-
ADP-ribose-polymerase inhibitors. To date, most reliable 
prognostic factors include the presence of residual disease 
after initial debulking surgery, the International Federation 
of Gynecology and Obstetrics (FIGO) stage, ascites volume, 
patient age, and histological subtype (Dembo et al. 1990; 
Vergote et al. 2001; Aletti et al. 2006; du Bois et al. 2009). 
However, widely accepted prognostic biomarkers are miss-
ing. Histologically, epithelial ovarian cancer (EOC) is clas-
sified into five main subtypes: high-grade serous, low-grade 
serous, mucinous, endometrioid, and clear cell histology, 
being distinguished in terms of phenotype, molecular back-
ground, and etiology (Kossaï et al. 2018). Considering the 
heterogeneity of ovarian cancer appears crucial for develop-
ing new prognostic and therapeutic strategies.
The VDR, as the receptor of the fat-soluble steroid vita-
min D, known as 1ɑ,25(OH)2D3 or calcitriol, belongs to 
the superfamily of nuclear receptors. VDR regulates gene 
expression by binding to target genes with promoters con-
taining a vitamin D response element (VDRE). VDR is a 
crucial mediator in calcium homeostasis and metabolism, 
inflammation, insulin-like growth factor signaling, and 
estrogen-related pathways and was identified in 30 different 
tissues (Valdivielso and Fernandez 2006; Holick and Chen 
2008).
In recent years, increasing evidence suggests that vitamin 
D and VDR play a pivotal role in gynecological cancers 
(Deuster et al. 2017). VDR expression is increased in ovar-
ian cancer and is associated with altered cancer cell prolif-
eration in an interplay with other growth-stimulating factors 
like androgens (Ahonen et al. 2000; Villena-Heinsen et al. 
2002; Friedrich et al. 2003; Anderson et al. 2006).
According to the increasing understanding of VDR`s role 
in ovarian cancer biology, expression analysis of VDR in 
different histological subtypes and of its correlation with 
survival was the primary aim in the current study.
Materials and methods
Patients and specimens
Ovarian cancer samples from 156 patients who under-
went surgery for EOC at the Department of Obstetrics 
and Gynecology, Ludwig-Maximilian’s-University Munich 
from 1990 to 2002, were examined in this study. Clinical 
data were collected from the patients’ charts and follow-
up data obtained from the Munich Cancer Registry. All 
specimens had been formalin  fixed and paraffin embed-
ded (FFPE). Patients with benign or borderline tumors 
were excluded and no patients had received neoadjuvant 
chemotherapy. Histological subtype and grading were 
determined by specialists at the Department of Pathology, 
Ludwig-Maximilian-University Munich. The staging was 
performed according to the WHO and FIGO Classifica-
tion (2014). The clinicopathologic characteristics of the 
analyzed ovarian cancer patients are listed in Table 1.
Table 1  Clinicopathologic characteristics of the ovarian cancer 
patients
Clinicopathologic parameters n Percentage (%)
Histology
 Serous 110 70.5



































  ≤ 60 years 83 53.2
  > 60 years 73 46.8
Histochemistry and Cell Biology 
1 3
Ethical approval
The Ethics Committee of the Ludwig-Maximilians-Univer-
sity, Munich, Germany, approved this study (approval num-
bers 227-09 and 18-392). All tissue samples utilized for this 
investigation were collected from material from the archives 
of the Department of Obstetrics and Gynecology, University 
Hospital, LMU Munich, Munich, Germany, having initially 
been used for pathological diagnostics. The diagnostic pro-
cedures were concluded before the current study was con-
ducted. During the analysis, the observers were fully blinded 
for patients’ data.
Immunohistochemistry
Immunohistochemistry was completed as earlier outlined 
by our laboratory (Scholz et al. 2012). For the detection 
of VDR, FFPE tissue sections were dewaxed with xylol 
for 20 min, and later dehydrated in ascending concentra-
tions of alcohol (70–100%). Afterward, they were exposed 
for epitope retrieval for 10 min in a pressure cooker using 
sodium citrate buffer (pH 6.0) holding 0.1 M citric acid and 
0.1 M sodium citrate in distilled water. After cooling, the 
slides were cleaned in PBS twice. Endogenous peroxidase 
activity was quenched by dipping in 3% hydrogen peroxide 
(Merck, Darmstadt, Germany) and in methanol for 20 min. 
Non-specific binding of the primary antibodies was blocked 
by incubating the sections with “diluted normal serum” 
(10 ml PBS containing 150 μl horse serum; Vector Laborato-
ries, CA) for 20 min at room temperature. Then, slides were 
incubated with the primary antibody [anti-vitamin D recep-
tor antibody, mouse IgG, monoclonal, Serotec, Puchheim, 
Germany, clone 2F4 (MCA3543Z)] at room temperature for 
60 min. After washing with PBS, slides were incubated in 
diluted biotinylated anti-serum secondary antibody (10 ml 
PBS containing 50 μl horse serum, Vector Laboratories, 
CA) for 30 min at room temperature. Following incubation 
with the avidin–biotin-peroxidase complex (diluted in 10 ml 
PBS, Vector Laboratories, CA) for 30 min and repeated PBS 
washing, visualization was conducted using substrate and 
chromagen 3,3′-diaminobenzidine (DAB; Dako, Glostrup, 
Denmark, catalog number K3468) for 8–10 min. Slides were 
then counterstained with Mayer’s acidic hematoxylin (Wal-
deck-Chroma, Münster, Germany, catalog number 2E-038) 
and dehydrated in an ascending series of alcohol followed 
by xylol. Negative and positive controls were employed to 
assess the specificity of the immunoreactions. Negative con-
trols (colored in blue) were conducted in placental tissue 
by the replacement of the primary antibodies by species-
specific (rabbit) isotype control antibodies (Dako, Glostrup, 
Denmark). For positive control, placental, vaginal and intes-
tinal tissues were utilized.
Staining evaluation
Specific VDR immunohistochemically staining reaction 
was observed in the nuclei and cytoplasm of the cells. The 
strength and distribution pattern of VDR staining was evalu-
ated using the semi-quantitative immunoreactive score (IR 
score, Remmele’s score). To obtain the IR score result, the 
optional staining intensity (0 = no, 1 = weak, 2 = moderate, and 
3 = strong staining) and the percentage of positive stained cells 
(0 = no staining, 1 ≤ 10% of the cells, 2 = 11–50% of the cells, 
3 = 51–80% of the cells and 4 ≥ 81%) were multiplied. In all 
156 (100%) EOC tissue samples, VDR staining was success-
fully performed. Cutoff scores for the IR scores were selected 
for the cytoplasmic VDR staining, taking into account the dis-
tribution pattern of IR scores in the collective. Cytoplasmic 
VDR staining was considered as low with IRS 0–2 and as 
high with IRS > 2.
For analyzing the images, the light microscope “Immuno-
histochemistry Type 307–148.001 512 686” by Leitz (Wetzlar, 
Germany) was used. The camera was produced by Fissler (IH-
Camera 3CCD Colour Video Camera). For image acquisition, 
the software “Discuss Version 4,602,017-#233 (Carl C. Hilg-
ers Technical Office) was used. Image bit depth: 24 mm; time 
and space resolution data: 760 + 574 pixel.
Statistical analysis
SPSS 25.0 (v25, IBM, Armonk, New York) was used for sta-
tistical analysis. The distribution of clinical–pathological vari-
ables was assessed with the Chi-square test. The Mann–Whit-
ney U test was utilized to compare IR scores of VDR between 
different clinical and pathological subgroups. Correlations 
between findings of immunohistochemical staining were 
measured using Spearman’s analysis. Through Kaplan–Meier 
(log-rank) estimates, survival times were analyzed. To iden-
tify an appropriate cutoff, the ROC curve was drawn, which 
is considered as one of the most reliable methods for cutoff 
point selection. In this context, the ROC curve is a plot rep-
resenting sensitivity on the y-axis and (1-specificity) on the 
x-axis (Nakas et al. 2010). Consecutively, the Youden index, 
defined as the maximum (sensitivity + specificity-1) (Youden 
1950), was used to find the optimal cutoff maximizing the sum 
of sensitivity and specificity (Fluss et al. 2005; Perkins and 
Schisterman 2006). For multivariate analyses, a Cox-regres-
sion model was used. p values less than 0.05 were considered 
to be significant.
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Results
VDR expression correlates with clinical 
and pathological data
The clinicopathologic characteristics of the analyzed ovarian 
cancer patients are listed in Table 1. Out of 156 successfully 
stained ovarian cancer specimens, 153 (98%) showed posi-
tive nuclear VDR expression. In the cytoplasm, 154 (99%) 
cases were VDR positive. Median (range) immunoreactivity 
scores (IRS) for VDR in nuclei and cytoplasm were 3 (0.9) 
and 3 (0.8), respectively.
Cytoplasmic VDR staining differed in the histological 
subtypes (p = 0.001): a high cytoplasmic VDR expression 
was found in serous, clear cell, and endometrioid histologi-
cal subtypes, and a low VDR expression in the mucinous 
subtype (Fig. 1). In comparison, nuclear VDR expression 
did not show a significant difference between the histological 
subtypes (p > 0.05).
VDR expression displayed correlations to clinical and 
pathological data (Table 2). A positive correlation was 
observed between high cytoplasmic VDR staining and 
positive lymph node status (p = 0.023; Cc = 0.236) as well 
as with a higher FIGO stage (p = 0.013; Cc = 0.203). High 
cytoplasmic VDR staining correlated with high-grade serous 
histology (p = 0.000; Cc = 0.298), as well as with grading 
from the other histologic subtypes (p = 0.006; Cc = − 0.225). 
In the nucleus, VDR does not correlate with clinicopatho-
logical data. Nuclear VDR and cytoplasmic VDR expression 
were observed not to correlate with each other (p = 0.070; 
Cc = 0.147).
High cytoplasmic VDR expression is associated 
with impaired overall survival
The median age of the patients was 58.7 [standard devia-
tion (SD) 31.4] years, with a range of 31–88 years. The 
median follow-up OS of the EOC patients was 34.4 (SD 
57.8) months. Cytoplasmic VDR expression was signifi-
cantly associated with a shorter OS (Fig. 2, 32.5 months vs. 
median not reached; p < 0.001).
Cytoplasmic VDR and clinical/pathological 
parameters are independent prognostic factors
In a cox regression multivariate analysis of the present 
cohort with established prognostic markers, cytoplasmic 
VDR expression proved to be a statistically independent 
prognostic factor (HR 2.218, p = 0.025), as well as cancer 
grading (HR 1.604, p < 0.001), FIGO stage (HR 1.947, 
p < 0.001) and patient’s age (HR 1.628, p = 0.019) (Table 3) 
were proved independent factors. Conversely, the prognostic 
impact of histological subtypes was not confirmed to be of 
independent significance.
Discussion
This present study focused on VDR expression in different 
histologic subtypes of EOC and its correlation with clinico-
pathological parameters. Patients with an increased cyto-
plasmic VDR expression were confirmed to have a signifi-
cantly impaired OS. Moreover, cytoplasmic VDR expression 
was identified as an independent prognostic factor for OS; 
therefore, these results suggest a functional role of VDR in 
ovarian cancerogenesis, which merits further investigations.
VDR has been traditionally considered as the nuclear 
receptor of vitamin D with a crucial role in calcium homeo-
stasis and metabolism (Holick and Chen 2008). However, 
increasing evidence suggests that vitamin D and VDR play 
a pivotal role in the development of ovarian cancer. Epide-
miological studies showed a reduced ovarian cancer risk in 
southern countries, indicating an association with the inhibi-
tion of vitamin D synthesis (Garland et al. 2006). Moreover, 
studies demonstrated an association between low circulating 
25-hydroxyvitamin D, a prehormone of vitamin D, and a 
higher ovarian cancer incidence (Bakhru et al. 2010; Yin 
et al. 2011; Walentowicz-Sadlecka et al. 2012; Anastasi et al. 
2016; Ong et al. 2016), while increased 25-hydroxyvitamin 
D levels at diagnosis seem to be associated with longer over-
all survival in ovarian cancer patients (Webb et al. 2015). 
25-Hydroxyvitamin D reduces proliferation and induces cell 
cycle arrest of ovarian cancer cells as well as in animal mod-
els (Jiang et al. 2003; Zhang et al. 2005; Thill et al. 2015). 
Furthermore, vitamin D is involved in epithelial–mesenchy-
mal transition (EMT), a crucial process in cancerogenesis 
and tumor progression. Vitamin D decreases the expression 
of relevant transcription factors of EMT and thereby reduces 
migration and invasion of SKOV-3 cells. This might explain 
the effect of vitamin D on ovarian cancer in vitro and in vivo 
(Hou et al. 2016).
VDR is expressed in both benign and malignant ovar-
ian tissues and influences the ovarian function by mediating 
estrogen biosynthesis and aromatase gene expression (Lurie 
et al. 2007). In vivo studies demonstrated that VDR-null 
mice show gonadal insufficiency and low aromatase activity.
Our findings are in line with previous reports showing 
that VDR expression is increased in ovarian cancer (Villena-
Heinsen et al. 2002; Friedrich et al. 2003; Anderson et al. 
2006; Agic et al. 2007). In 2010, Silvagno et al. analyzed 
the correlation between VDR expression and clinicopatho-
logical parameters, reporting predominantly cytoplasmic 
staining for VDR in ovarian cancer tissue (Silvagno et al. 
2010). A comparable cytoplasmic staining pattern of VDR 
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Fig. 1  Detection of VDR with immunohistochemistry: a high VDR 
cytoplasm staining (IRS > 2) in ovarian cancer with serous, b clear 
cell, c endometrioid, (d) and mucinous histology. e VDR-negative 
control (f) and positive control in human placenta tissue. 10× (scale 
bar = 200 µm) and 25× (inserts, scale bar = 100 µm) magnification
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was noticed in malignant melanoma, colon and vulvar can-
cer affecting tumor progression and prognosis (Matusiak 
et al. 2005; Salehin et al. 2012; Hutchinson et al. 2018). 
However, the functional effect of cytoplasmic VDR cannot 
be described by its nuclear signal cascade. Interestingly, 
VDR may mediate its molecular effect through two different 
pathways. While the classic nuclear pathway involves genes 
with promoters containing a vitamin D response element 
(VDRE) and consecutively regulates gene expression, the 
non-nuclear VDR-mediated pathway follows different mech-
anisms: VDR interacts with c-Src in the plasma membrane 
activating c-RAF and subsequently the MEK1/2/ERK1/2 
pathway (Cordes et al. 2006; Buitrago and Boland 2010; 
Han et al. 2010; Doroudi et al. 2014). The extracellular 
signal-regulated kinase (ERK) pathway is one of the major 
signaling cascades of the MAPK signaling pathway, which 
plays a crucial role in cancerogenesis, including cell pro-
liferation, differentiation, migration, apoptosis, and chem-
oresistance. Preclinical and early clinical studies underline 
the relevance of the ERK/MAPK pathway in ovarian cancer 
(Hsu et al. 2004; Bartholomeusz et al. 2006; Al-Ayoubi et al. 
2008; Ohta et al. 2009; Vergara et al. 2012; Chang et al. 
2012; Fujisawa et al. 2012; Wang et al. 2014; Su et al. 2016; 
Bai et al. 2016; Ma et al. 2018). In this context, high MAPK 
activity in tumors was associated with high cytoplasmic 
VDR expression, indicating an association of these path-
ways, which could lead to a crucial role of the non-nuclear 
VDR pathway in cancerogenesis. Hutchinson et al. showed 
a similar interaction in malignant melanoma (Hutchinson 
et al. 2018). Decreased nuclear and high cytoplasmic VDR 
expressions were associated with malignant progression in 
terms of dermal invasion and metastasis. Malignant melano-
mas that retained exclusive nuclear VDR at the tumor base 
Table 2  Correlation between high cytoplasmic/ nuclear VDR expres-
sion and and clinicopathological data
Clinicopathologic data and VDR expression were correlated to each 
other using Spearman’s correlation analysis. Significant correlations 










pT 0.133 0.122 0.653 -0.037
pN 0.023* 0.236 0.288 0.112
FIGO 0.013* 0.203 0.620 0.041
Grading
 Low-grade serous 0.121 − 0.125 0.065 0.150
 High-grade serous 0.000** 0.298 0.155 − 0.116
 Clear cell, endometri-
oid and mucinous-G1 
to G3
0.006** − 0.225 0.883 -0.012
Fig. 2  Kaplan–Meier estimate of cytoplasmic VDR: High cytoplasmic VDR expression (IRS > 2) was associated with impaired overall survival 
(HR 2.218, 32.5 months vs median not reached; p < 0.001)
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did not metastasize in this study. Furthermore, high MAPK 
activity in tumors expressing cytoplasmic VDR was associ-
ated with increased cell growth and worsened prognosis. In 
contrast, MAPK inhibition produced nuclear migration of 
VDR and decreased cell viability in vitro.
Inhibition of the MAPK pathway in EOC has been con-
sidered as a potential approach in subgroups of patients with 
specific histologic profiles, especially low-grade histology, 
although targeted therapies have so far failed to exhibit reli-
able therapeutic effects (Farley et al. 2013; Han et al. 2018; 
Fernandez et al. 2019). Thus defining subgroups of suitable 
patients for MAPK inhibition remains highly important.
Our data suggest cytoplasmic VDR as a potential predic-
tive biomarker that might distinguish between tumors which 
are MAPK inhibitor sensitive and those which are not. Thus, 
cytoplasmatic VDR could be used to predict which patients 
profit from an MAPK inhibitor therapy.
Nevertheless, further studies are needed to prove our 
hypothesis as a basis for a better understanding of therapy 
in EOC subgroups.
Acknowledgements Open Access funding provided by Projekt DEAL. 
The authors are grateful to Mrs. Christina Kuhn for excellent technical 
assistance.
Author contributions BC, UJ, and FT conceived and designed the 
experiments. ED, CS, and UJ participated in immunohistochemistry 
analysis and performed the statistical analysis. DM and ES supervised 
immunohistochemistry as gynecologic pathologists and participated in 
immunohistochemistry analysis as well as in the design and coordina-
tion of the study. BC and FT wrote the paper. ED, YL, CS, TK, AH, SF, 
AB, and SM revised the manuscript for important intellectual content. 
All authors analyzed and interpreted the results and read and approved 
the final manuscript.
Funding This research did not receive any specific grants from any 
funding agency in the public, commercial, or not-for-profit sector.
Data availability The datasets generated and/or analyzed 
during the current study are available from the correspond-
ing author upon reasonable request.Code availability Data 
are available from the corresponding author on reasonable 
request.
Compliance with ethical standards 
Conflict of interest Thomas Kolben holds stock of Roche AG and 
his relative is employed at Roche AG. Anna Hester has received a re-
search grant from the “Walter Schulz” foundation and advisory board, 
speech honoraria, and travel expenses from Roche and Pfizer. Research 
support, advisory board, honoraria, and travel expenses from Astra-
Zeneca, Clovis, Medac, MSD, Novartis, PharmaMar, Roche, Sensor 
Kinesis, Tesaro, and Teva have been received by Sven Mahner and oth-
ers from AstraZeneca, Medac, PharmaMar, Roche, Tesaro by Fabian 
Trillsch. All other authors declare no conflict of interest. All the above-
mentioned companies did not influence the study design, data collec-
tion and analysis, decision to publish, or preparation of the manuscript.
Ethical approval This study was approved by the Ethics Committee of 
the Ludwig-Maximilians-University, Munich, Germany (approval num-
bers 227–09 and 18–392). The ovarian cancer specimens were obtained 
in clinically indicated surgeries and initially used for histopathologi-
cal diagnostics. When the current study was performed, all diagnostic 
procedures were completed, and the patients’ data were anonymized. 
The ethical principles adopted in the Declaration of Helsinki 1975 
have been respected.
Consent for publication All authors have read the manuscript and agree 
to its publication.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Table 3  Multivariate analysis
A multivariate Cox regression model was established to investigate independency of prognostic factors. 
Significant independent factors are indicated by asterisks (*p < 0.05; **p < 0.01)
CI confidence interval
Covariate Coefficient Hazard ratio 95% CI p value
Lower Upper
Histology (serous vs other) − 0.037 0.963 0.637 1.457 0.86
Grading (low vs high) 0.472 1.604 1.158 2.138 0.000**
FIGO (I, II vs III, IV) 0.666 1.947 1.409 2.690 0.000**
Patients’ age (≤ 60 vs > 60 years) 0.487 1.628 1.082 2.449 0.019*
VDR cytoplasmic 0.797 2.218 1.106 4.448 0.025*
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